ArticleBMC infectious diseases2026
Comparable tolerability, symptom worsening, and treatment completion rates among different Helicobacter pylori eradication regimens in children.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe tolerability of Helicobacter pylori (H. pylori)eradication regimens in children remains a clinical concern, particularly regarding gastrointestinal adverse effects and treatment discontinuation. The aim of this study was to compare the tolerability of different H. pylori eradication regimens in children by evaluating treatment-related symptoms, symptom worsening during therapy, and treatment completion rates.
methodsPediatric patients with endoscopically confirmed H. pylori infection were treated with clarithromycin-based, metronidazole-based, or bismuth-containing regimens. All eradication regimens were administered for 14 days. Symptom severity was graded using a standardized scoring system, and stool pattern was assessed using the Bristol Stool Scale. Symptom worsening was defined as an increase compared with baseline. Within-group comparisons were performed using the Wilcoxon signed-rank test, and between-group differences were analyzed using chi-square or Fisher's exact test. A p value < 0.05 was considered statistically significant.
resultsIn the overall study population, nausea, vomiting, metalic taste and anorexia scores increased significantly during treatment compared with baseline (Wilcoxon signed-rank test, p < 0.05). However, symptom worsening rates and stool pattern changes did not differ significantly among treatment groups (all p > 0.05). A total of 16 patients discontinued therapy. Discontinuation rates were 9.1% in the clarithromycin-based group, 2.4% in the metronidazole-based group, and 12.0% in the bismuth-containing group, with no statistically significant difference between groups (p = 0.204). Vomiting was the most common reason for treatment interruption, followed by diarrhea.
conclusionThe evaluated H. pylori eradication regimens showed comparable tolerability and treatment completion rates in children. Treatment selection may therefore be guided primarily by eradication efficacy and antimicrobial resistance patterns rather than concerns regarding adverse effects alone.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.